patient was followed closely for 8 weeks while information was retrieved from the treating institution. During this short period, there was significant apical tumor growth. Additionally, there was a clear clinical change compared to the last documented photos from 5 years prior at the treating institution. Enucleation was recommended. Pathological analysis confirmed the diagnosis of recurrent choroidal melanoma at the apex of the treated lesion, at the site of prior biopsy. Systemic surveillance was negative for metastatic disease. Conclusion: Current literature suggests the majority of choroidal melanoma recurrences occur within 5 years following treatment. However, this case of recurrence 10 years after brachytherapy emphasizes the importance of life-long ophthalmic care for these patients. Additionally, this case demonstrates the possibility of a rare recurrence at a prior biopsy site.
Introduction
Brachytherapy remains the standard of care for globesalvaging treatment of choroidal melanoma. However, according to the Collaborative Ocular Melanoma Study (COMS) trial, the risk of treatment failure post-brachytherapy was found to be 10% at 5 years [1] . Risk factors for treatment failure were older age, greater tumor thickness, greater basal dimension of the tumor, and proximity of the tumor to the foveal avascular zone [2, 3] . Most recurrences occur at the posterior margin of the tumor [4] . The majority of recurrences are found in the first 2 years [2] , and recurrences after 5 years are relatively rare [5] . Recurrence has also been associated with the development of metastatic disease [6] . Herein we describe a late apical recurrence of choroidal melanoma at the site of the prior biopsy noted 10 years after successful treatment with 125 I brachytherapy.
Case Report
A 78-year-old Caucasian male was treated for choroidal melanoma of the left eye 10 years earlier with 125 I plaque brachytherapy at a dose of 85 Gy to the apex of the tumor. At that time, the treating institution performed diagnostic transvitreal biopsy from the pars plana with a 25-G needle at the apex of the tumor. Gene expression profiling was not done on the biopsy sample. He relocated to another state and did not continue routine monitoring of his treated tumor for many years until his presentation at our institution. He had no new visual complaints and denied any ocular pain. His vision was poor, but stable at count fingers in the affected eye. Dilated fundus examination revealed a minimally elevated fibrotic dome-shaped pigmented tumor with surrounding chorioretinal atrophy consistent with treated choroidal melanoma; at the apex of the tumor was an elevated amelanotic nodule. The fundoscopic photo at diagnosis (Fig. 1a) shows a clear change with an amelanotic nodule at the apex indicating a possible recurrence; however, it was not clear whether this was new given the lack of previous photos. B-scan ultrasonography demonstrated a domeshaped choroidal lesion measured at 8.8 × 9.9 × 4.6 mm (Fig. 1b) .
Given the concern for possible recurrence, the patient was asked to return for short-term follow-up while prior treatment records were requested. Eight weeks later, clinical examination and fundus photography demonstrated clear growth compared to the previous exam with the majority of the growth arising from the apical component (Fig. 1c) . Additionally, on B-scan ultrasonography, the lesion had grown to 9.66 × 11.84 × 6.32 mm (Fig. 1d) , confirming the diagnosis of a late tumor recurrence following brachytherapy.
Fundus photographs obtained from the treating institution (Fig. 1e ) demonstrated a small pigmented nodule at the apex of the lesion and confirmed clear growth of the now amelanotic apical nodule which occurred at the site of prior fine needle aspiration biopsy (FNAB). This photography was taken after the FNAB. The primary tumor was 2 mm in thickness at the time of the diagnostic biopsy, which came back as undiagnostic. Five years later, the lesion had grown, although still small, measuring 7.5 × 7 mm in basal diameter and 3.5 mm in thickness. At that time, the patient was treated with a notched COMS style 125 I plaque, at a dose of 85 Gy to the apex, and was documented to have satisfactory postbrachytherapy regression until he was lost to follow-up. Prebrachytherapy photographs from the treating institution were not available.
At the time of recurrence, CT scan of the chest, abdomen, and pelvis was negative for metastatic disease. Given the patient's poor vision and active disease post-brachytherapy, an enucleation was performed. Histopathological analysis of the enucleated eye confirmed active choroidal melanoma recurrence, predominantly spindle B cell type, at the site of a break in Bruch's membrane and retina likely from the prior FNAB (Fig. 2) . No extrascleral extension was identified. Cystoid retinal degeneration overlying the tumor and in the peripheral retina was noted, as well as focal choroidal fibrosis adjacent to the tumor base, consistent with previous brachytherapy. The patient did not want further testing, and additionally the tissue had been exposed to radiation, thus genetic studies were not performed on the enucleated tumor.
Discussion
The goal of plaque brachytherapy is local tumor control, which allows for globe salvage [1, 3] . Prior studies suggest that following brachytherapy there is often greater than 90% local tumor control for choroidal melanomas [1, [7] [8] [9] , with recurrence rates ranging from 0 to 18% [3, 7] . The COMS reported a 10.3% rate of local tumor recurrence at 5 years following 125 I brachytherapy [1] . The COMS trials [2] also reported that age over 50 has a nearly 3 times greater risk of recurrence, which was the only risk factor for recurrence identified in our patient; other risk factors include greater apical height and proximity to the fovea [2, 10] . Improved rates of local tumor control have been achieved by smaller studies. A series by the University of Southern California, using 3D imaging for plaque planning, achieved a local tumor control rate of 97% at 5 years [8] . Another study used intraoperative ultrasound guidance for brachytherapy, and found a statistically lower rate of 2-year local treatment failure than the COMS trial [9] . In a study by Char et al. [5] , the annual incidence of recurrent melanoma after 125 I brachytherapy was 2.8% between 0 and 5 years, and 1.9% between 5 and 15 years. These prior studies indicate that brachytherapy provides highly effective local tumor control, however recurrences after brachytherapy do occur and late recurrences (>5 years) have been reported. Char et al. [5] found that the mean time to recurrence following brachytherapy was 3.6 years, and reported one case of local tumor recurrence after 15.3 years. Sánchez-Tabernero et al. [11] reported a similar mean time to local treatment failure of 3.7 years, with one case recurring 12 years after treatment. In a meta-analysis of 9 studies, Bellerive et al. [10] reported that the 5-year local recurrence rate was estimated at 6%.
The vast majority of melanoma recurrences following brachytherapy occur at the tumor margin, particularly the posterior tumor margin, due to plaque placement [4, 10, 12] . An apical recurrence is less common, especially given that our patient's tumor was <3.5 mm at the time of brachytherapy. It is possible that a break in Bruch's membrane secondary to FNAB predisposed to the recurrence Color version available online occurring mainly at the biopsy site with an enlarging amelanotic nodule. Rouberol et al. [13] reported Bruch's membrane rupture, defined by a bud on the base of the fundus tumor associated with a mushroom shape on ultrasound, as a statistically significant risk factor for recurrence. In our case, it is not known what effect the biopsy had, if any. There have been no similar cases reported in the literature. FNAB is increasingly employed for diagnostic and prognostic molecular genomic analysis [14] [15] [16] , and many prior studies have shown that FNAB does not increase the risk of local treatment failure, orbital dissemination, or metastasis [14, [17] [18] [19] . Failure to achieve local control of choroidal melanoma from radiation therapy has been shown to be associated with an increased metastatic risk [6, 11, 20] . Corroborating results from other authors, the Ophthalmic Oncology Task Force [6] found that local tumor recurrence increased the risk of metastasis by a hazard ratio of 6.28. Similarly, the COMS trials [2] reported that local treatment failure after brachytherapy was weakly associated with reduced survival, with an adjusted risk ratio of 1.5. However, associations between treatment failure and metastatic or survival risk may have confounding factors; tumors that fail local treatment may also be more aggressive in nature, with a tendency to both recur and metastasize [20] . Fortunately, our patient was both 10 years following brachytherapy and negative for metastatic disease, suggesting a less aggressive phenotype clinically, but gene expression profiling was not done in this case.
Herein we report a case of apical choroidal melanoma recurrence at the site of prior biopsy after 10 years of stability following 125 I brachytherapy. Clinical documentation of growth confirmed suspicion for late focal relapse, and was further verified by histopathology of the enucleated globe. Recurrence is generally seen in the first few years after brachytherapy [2, 5] ; however, as this case demonstrates, late local relapses may occur and clinicians must continue to monitor patients and counsel them on the need for life-long ophthalmic examinations. In addition, although FNABs are both safe and prognostically useful for choroidal melanoma, the mechanical disruption of the tumor at the apex in this rare case may have predisposed to recurrence.
